Events

VIRTUAL - Doctor in the House: Dr Lyerly on Breast Cancer Vaccine study by Duke University

When: 09/14/2020 5:00 PM - 6:30 PM



Dr H. Kim Lyerly - Distinguished Professor of Immunology and Surgery at Duke University

Virtual Session begins promptly at 5:00 PM
Please register above in order to receive the link to join the program.

 NOTE: This session will be delivered online using Zoom.  You can participate using your computer, smartphone, or tablet.  There is no cost involved or software to load.   All you need is the meeting link and password, which we will provide via email confirmation when you register above (using the button at the top of this session description).   We suggest using the provided meeting link a few minutes prior to the start time of the session.   If you don't receive a confirmation email from us within an hour of registering, please check your SPAM folder or email : lverner@carolinabreastfriends.org

 

Session Description:
Please join us as Dr Lyerly discusses an innovative vaccine trial for Her 2 positive breast cancer that he helped to write at Duke University.  The vaccine is currently in Phase 2 trials and showing very promising results in both tumor reduction and long-term tumor free survival.  This investigational vaccine is part of an "effective" two-drug strategy being studied to fight breast cancer.   The research collected from this clinical trial was recently published in the journal of Clinical Cancer Research. The vaccine is specifically for patients with Her 2 positive breast cancer, targeting resistant genes and creating anti-tumor immune responses.  The study notes that the vaccine can work on its own, but is better used as part of a 2 drug regimen. The second drug being used with this vaccine is pembrolizumab.  This study has shown promising results for both tumor reduction and "long-term tumor free survival." This vaccine combination is currently being tested in a Phase 2 study led by Dr. Lyerly and other Duke researchers. The study has received funding from the National Cancer Institute, the Department of Defense, and the Susan G. Komen Foundation.

Click the following link to read more about the research: https://www.bizjournals.com/bizwomen/news/out-of-the-office/2020/08/duke-study-new-breast-cancer-vaccine-shows-succes.html 


Instructor Bio: 

Dr. Lyerly holds the George Barth Geller Chair of Cancer Research at Duke, and is Professor of Surgery, Pathology and Immunology at the Duke University Medical Center. He has been named by his peers as one of North Carolina's most outstanding clinical physicians. In 2008, Dr. Lyerly was appointed to the National Cancer Advisory Board (NCAB) by President George Bush and was named chair on the Cancer Centers sub-committee of the NCAB and served on the Global Health sub-committee. Dr. Lyerly has been actively involved in global cancer research and education for many years. He has research collaborations in cancer care, cancer immunotherapy, and cancer genomics with faculty members in China and India. He has been a faculty member of the Medical Oncology Group of Australia Clinical Trials Workshop, and has conducted clinical trials workshop in Singapore, China, India, and Pakistan. He currently leads a workshop with the US Food and Drug Administration directed to accelerating entry in the markets for cancer treatment, which is currently expanding to address the process of cancer drug development globally.



Always check the CBF website for updates on the current month's calendar.

 

Contact CBF for more details:
Email: lverner@carolinabreastfriends.org



Pink House Disclaimer....
Programs at Carolina Breast Friends should not be used as a substitute for any treatment. Sessions are intended to provide community and general support for breast cancer survivors. They are not intended to diagnose, treat, cure or prevent any disease. Consult your doctor if you are in any way concerned about activities that are part of an offered program.

 

Contact Us

  • Open Monday to Friday 10:00-5:00
  • 1607 E Morehead Street, Charlotte NC 28207

Sign up to receive our Newsletter

Unsubscribe